ReviewExpert review of vaccines2012
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.
Review in Expert review of vaccines, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.PLoS neglected tropical diseases · 2023Trial
- Article
- Vector-borne diseases and their role in COVID-19 dynamics and death rates: focus on India.Folia microbiologica · 2025Article
- A Prior Usutu Virus Infection Can Protect Geese from Severe West Nile Disease.Pathogens (Basel, Switzerland) · 2023Article
- Review
- Review
- Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.Virulence · 2021Article
- Structure of Usutu virus SAAR-1776 displays fusion loop asymmetry.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Global emergence of West Nile virus: Threat & preparedness in special perspective to India.The Indian journal of medical research · 2021Review
- A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.NPJ vaccines · 2020Article
- Current Progress of Avian Vaccines Against West Nile Virus.Vaccines · 2019Review
- West Nile virus infection in individuals with pre-existing Usutu virus immunity, northern Italy, 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Article
- West Nile virus vaccines - current situation and future directions.Human vaccines & immunotherapeutics · 2019Review
- Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development.F1000Research · 2018Article
- Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection.PLoS pathogens · 2017Article
- Tick-borne encephalitis in Japan, Republic of Korea and China.Emerging microbes & infections · 2017Review
- Zika virus infection confers protection against West Nile virus challenge in mice.Emerging microbes & infections · 2017Article
- Vaccinations for Neuroinfectious Disease: A Global Health Priority.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Host response: Mice and humans in the bubble.Nature microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Serological cross-reactivity providing cross-protective immunity between antigenically related viruses is a cornerstone of vaccination. It was the immunological basis for the first human vaccine against smallpox introduced more than 200 years ago, and continues to underpin modern vaccine development as has recently been shown for human papillomavirus vaccines, which confer cross-protection against other oncogenic papillomavirus types not present in the vaccine. Here, we review the feasibility of cross-protective vaccination against an antigenic group of clinically important viruses belonging to the Japanese encephalitis serocomplex in the Flaviviridae family. We will discuss evidence suggesting that 'new generation' flavivirus vaccines may provide effective cross-protective immunity against heterologous Japanese encephalitis serocomplex viruses, and appraise potential risks associated with cross-reactive vaccine immunity. The review will also focus on the structural and mechanistic basis for cross-protective immunity among this group of flaviviruses, which is predominantly mediated by antibodies against a single viral surface protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.